Frontlight ResearchEarly access
CompletedPhase 2
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
Key facts
- Who runs it
- Technophage, SA
- Where
- Los Angeles and Webster, United StatesSee the 2 sitesAlso in 2 other countries, 13 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 76 people enrolled
- Started
- 8 Nov 2023
- Ended
- 19 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- TP-102
- Placebo
- Record updated
- 22 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Aged ≥18 years old
- Established diagnosis of Diabetes Mellitus (type I or II)
- Glycosylated hemoglobin (HbA1c) value < 12.0%
- Designated foot infection meets the following criteria:
- Present for at least 3 weeks
- Below-ankle, full-thickness, cutaneous ulcer
- Wound area (after debridement, if applicable) 1 to 20.0 cm2
- PEDIS infection grade 2 or 3
- PEDIS perfusion grade 1 or 2
- PEDIS depth grade 1 or 2 (grade 3 at the discretion of the investigator e.g. if they have received appropriate surgical treatment to remove infected bones)
- Diabetic foot infection with at least one target bacterial strain (Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii), susceptible to the TP-102 bacteriophage cocktail, as assessed from wound cultures
- Patients of suitable physical and mental health as determined by the Investigator on the basis of medical history and general physical examination
- Patients of childbearing potential must have a negative serum pregnancy test at screening
- ICF signed voluntarily before any study-related procedure is performed, indicating that the patient understands the purpose of, and procedures required in the study and is willing to participate in the study
Who cannot take part
- Patient receiving hyperbaric oxygen therapy (HBOT), negative pressure wound therapy (NPWT), bioengineering skin (BES) substitutes and/or growth factors
- Currently participating in another clinical trial or having participated in a previous clinical trial with receipt of an investigational product within 30 days of the first administration of IP
- Participants with hypersensitivity to any component of investigational products
- Infected study ulcer less than 2 cm away from other ulcers, in the case of multiple ulcers
- Presence of active malignant or benign tumors of any kind, (with exception to nonmelanoma skin cancer as per investigator's discretion)
- A condition that, in the opinion of the Investigator, could compromise the well-being of the patient or course of the study, or prevent the patient from meeting or performing any study requirements
- Patient which, in the opinion of the investigator, may not comply with study related procedures
- Being pregnant or breastfeeding
Where in United States
Also in 2 other countries, 13 sites
- Clemente Clinical ResearchLos Angeles, United States
- Tranquil Clinical ResearchWebster, United States
About the trial
What the trial wants to find out
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
The 2 groups in the trial
- TP-102Treatment being tested
Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
- PlaceboPlacebo, for comparison
Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2 CT to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients With DFI
- Record updated
- 22 December 2025